J&J Rybrevant Update Could Bode Positively For AstraZeneca’s Tagrisso

 
• By Jessica Merrill

A Phase III trial of Rybrevant with lazertinib versus Tagrisso in first line EGFR-positive NSCLC is continuing after an interim analysis, surprising some investors who thought it might be stopped early for efficacy.

Question mark
Investors questioned the meaning behind a Rybrevant trial continuing to a final analysis • Source: Shutterstock

More from Clinical Trials

More from R&D